生物学的製剤抵抗性の活動性強直性脊椎炎患者におけるupadacitinibの有効性と安全性: 二重盲検無作為化プラセボ対照フェーズ３試験
Ann Rheum Dis 2022 doi:10.1136/annrheumdis-2022-222608
Van der Heijde et al., carried out a study to show whether upadacitinib offers an effective treatment option for bDMARD-naïve and bDMARD-IR patients with active AS. Their results indicated that upadacitinib 15 mg significantly improved the signs and symptoms of active AS. The treatment was well tolerated for 14 weeks in bDMARD-IR patients, consistent with results observed in the upadacitinib AS bDMARD-naïve study.